Sign in
Active, not recruitingPhase 4

20% Albumin vs. Balanced Salt Solution as Resuscitation Fluid in Cirrhosis With Sepsis Induced Hypotension

Key facts

Who runs it
Post Graduate Institute of Medical Education and Research, Chandigarh
Where
India1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 4
People taking part
150 people, planned
Started
15 Aug 2020
Expected to end
Dec 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • 20% albumin
  • Balanced salt solution
Record updated
13 November 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (15)Hide the full registry criteria

Who can take part

  • Clinical/Imaging or Biopsy proven liver cirrhosis of any etiology who consent for enrolment
  • Hypotension (Mean arterial pressure <65mmHg or Systolic blood pressure <90mmHg)
  • Aged between18-65 yrs

Who cannot take part

  • Already received colloid or more than 2 litres of fluid without baseline echocardiographic assessment
  • Severe pre-existing cardiopulmonary disease
  • Acute Respiratory Distress Syndrome (ARDS)
  • Active bleeding like variceal bleed
  • Chronic renal disease - End Stage Renal Disease (ESRD)/ patient on renal replacement therapy
  • Admission to ICU following liver transplantation, burns, cardiac surgery
  • Previous adverse reaction to human albumin solution
  • Already on vasopressors/inotropes
  • Cerebrovascular events
  • Brain death or likely brain death within 24 hours
  • Pregnant or lactating women
  • Informed consent refused by patient or attendants

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Patients with cirrhosis patients have a high incidence of sepsis which can trigger decompensation and may result in prolonged hospital stay and increased mortality. About 30%-50% admissions of patients with cirrhosis have sepsis at presentation and about 15% patients admitted to hospital develop sepsis during the hospital stay . After infection develops, the patient may develop acute kidney injury (AKI), shock, encephalopathy or disseminated intravascular coagulation (DIC) further decreasing the chances of survival. In fact, sepsis in patients with cirrhosis is associated with 15% in-hospital mortality, approximately double that of patients without sepsis. So, sepsis is directly responsible for 30-50% of deaths in cirrhosis . Therefore, it is critical to manage sepsis early and appropriately in cirrhosis to reduce the complications and mortality. Early administration of fluids, source control and empirical antibiotics along with vasopressors if refractory shock are essential components of treatment in all patients with sepsis. Currently, the most accepted strategy for early sepsis management is a combination of early goal directed therapy (EGDT) and physiological parameters, such as urine output, lactate clearance, and administration of antibiotics, within 1 hour of presentation . The use of central venous pressure assessment is fallacious for gauging adequacy of fluid resuscitation in cirrhosis, and the difficulty of performing echocardiographic assessments in the setting of ascites and cirrhotic cardiomyopathy is also well described .

The 2 groups in the trial

  • 20% Albumin armTreatment being tested

    20% Albumin in a dose of 20-40 gm per day as infusion over 12-24 h

    Treatment: 20% albumin and Balanced salt solution

  • Balanced salt solution armExisting treatment, for comparison

    Fluid resuscitation protocol includes use of an immediate 500 ml bolus of crystalloid i.e., balanced salt solution (BSS) or 0.9% normal saline (Rescue phase), followed by 20 ml/kg fluid in the first 6 hours titrated to target MAP of \> 65mmHg.The second phase of fluid resuscitation (Optimization phase) will be performed as per IVC targets, attainment of lactate clearance, and LUS score to prevent overload.

    Treatment: Balanced salt solution

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
To Compare 20% Albumin vs. Balanced Salt Solution as Resuscitation Fluid and Identify Fluid Responsiveness Criteria in Critically Ill Patients With Cirrhosis With Sepsis Induced Hypotension; a Prospective Randomized Controlled Trial.
Record updated
13 November 2026